What is Intensity Therapeutics?
Intensity Therapeutics operates at the intersection of immunology and oncology, focusing on the discovery and commercialization of novel drug candidates designed to attenuate tumors. By utilizing a unique approach to immune system activation, the company aims to improve patient outcomes and quality of life. As a clinical-stage entity, Intensity Therapeutics is currently navigating the complex regulatory and development landscape required to bring breakthrough cancer treatments to market. Its market position is defined by its commitment to precision medicine and its ability to attract institutional backing from firms specializing in high-growth biotechnology and medical innovation sectors.
How much funding has Intensity Therapeutics raised?
Intensity Therapeutics has raised a total of $25.4M across 5 funding rounds:
Angel/Seed
$1.8M
Private Equity
$500K
Series A
$10M
Series B
$6.5M
Other Financing Round
$6.6M
Angel/Seed (2013): $1.8M, investors not publicly disclosed
Private Equity (2015): $500K, investors not publicly disclosed
Series A (2016): $10M supported by SalvaRx Group PLC, VCapital, FastForward Innovations, and Batterson Venture Capital
Series B (2018): $6.5M, investors not publicly disclosed
Other Financing Round (2025): $6.6M, investors not publicly disclosed
Key Investors in Intensity Therapeutics
VCapital
VCapital is a Chicago-based venture capital firm focused on early-stage companies, specializing in high-growth sectors including biotechnology and medical devices.
FastForward Innovations
FastForward Innovations Limited focuses on funding disruptive technologies and provides strategic insights for innovation-driven projects across various sectors.
Batterson Venture Capital
Batterson Venture Capital is a seasoned investment firm with deep expertise in biotech and high-technology, providing operational support and capital to early-stage enterprises.
What's next for Intensity Therapeutics?
With the recent capital injection, Intensity Therapeutics is well-positioned to scale its clinical development programs and refine its therapeutic platform. The strategic focus will likely shift toward expanding trial capacity and strengthening its intellectual property portfolio. By leveraging this latest financing, the company aims to reach key clinical inflection points that will validate its technology's efficacy in human subjects. As the firm matures, the emphasis will remain on achieving regulatory milestones and exploring potential commercial partnerships that can facilitate the transition from clinical development to market-ready oncology solutions, ensuring long-term value creation for stakeholders and improved therapeutic options for patients.
See full Intensity Therapeutics company page
